Novo amycretin safety ‘not quite as clean as we’d like,’ says Deutsche Bank

Deutsche Bank says Novo Nordisk’s Phase 1 pipeline asset amycretin is “at minimum a key component of the medium-term obesity pipeline” and following the full presentation of early data, which took place at EASD in Madrid this morning, the firm says it views the data as “a neutral to a very minor negative” as the safety data is “not quite as clean as we’d like to see.” The safety issues are “not at the level of Roche’s ‘388 earlier this week,” but they are “a little high for the BID dose in particular” in terms of nausea and vomiting that were almost double the QD dose rates, the analyst tells investors. Deutsche Bank has a DKK 1,100 price target and Buy rating on Novo Nordisk shares.